达格列净片致严重便秘1例分析
One case of severe constipation caused by dapagliflozin
卢靖 1喻珊珊 2童菲 2林卓慧 3宋路瑶2
作者信息
- 1. 南方医科大学珠江医院药学部,广东 广州 510280;广州市荔湾中心医院药剂科,广东 广州 510170
- 2. 南方医科大学珠江医院药学部,广东 广州 510280
- 3. 广州市荔湾中心医院药剂科,广东 广州 510170
- 折叠
摘要
目的 提高医务人员对达格列净片致严重便秘的警惕性,为达格列净的安全使用提供参考.方法 分析1例由达格列净片导致严重便秘患者的诊疗经过,对相关文献进行归纳与总结,探讨钠-葡萄糖共转运体2抑制剂(SGLT-2i)导致严重便秘的发生情况、可能机制和防治措施.结果 患者在使用达格列净片后出现严重便秘,停药后患者便秘症状好转,再次使用达格列净片后患者又出现便秘,立即停药并予润肠通便治疗后,便秘症状好转.其不良反应因果关系评估为"肯定",故判断该患者严重便秘由达格列净片所致.结论 便秘不仅严重影响患者生活质量,还可能诱发心血管事件,应加强对达格列净片及SGLT-2i类药物致便秘不良反应的重视及用药教育.
Abstract
Objective To remind health care professionals to be more alert to the risk of severe constipation associated with dapagliflozin and to provide reference for safe use of this drug.Methods The clinical process of treating a patient who developed severe constipation after taking dapagliflozin tablets was analyzed.Based on related literature,the possible mechanisms and treatment regimens of severe constipation caused by sodium-glucose cotransporter 2 inhibitors(SGLT-2i)were studied.Results One patient developed severe constipation after taking dapagliflozin.After discontinuation of the drug,the patient's constipation improved.However,upon re-administration of dapagliflozin,the patient relapsed into constipation.Immediately after drug withdrawal and treatment with laxatives to moisten the intestines,the patient's conditions improved.The causal relationship of adverse reactions was defined as"definite",so the severe constipation of this patient was considered to have been caused by dapagliflozin.Conclusion Constipation poses a significant threat to patients'quality of life and may potentially precipitate cardiovascular events.Therefore,it is imperative to enhance clinicians'awareness and pharmacological surveillance regarding the adverse effects of constipation associated with dapagliflozin and SGLT-2i.
关键词
达格列净/便秘/钠-葡萄糖共转运体2抑制剂/胃肠系统疾病/药品不良反应Key words
dapagliflozin/constipation/sodium-glucose cotransporter-2 inhibitors(SGLT-2i)/gastrointestinal disorders/drug adverse reaction引用本文复制引用
基金项目
广东省医院协会医院药学科研专项基金(YSGL-202202)
广州市科技计划项目(202102020539)
出版年
2024
NETL
NSTL
万方数据